Adaptive Biotechnologies, which provides an immunosequencing platform for diagnosing and treating diseases, filed on Thursday with the SEC to raise up to $230 million in an initial public offering.
The Seattle, WA-based company was founded in 2009 and booked $59 million in sales for the 12 months ended March 31, 2019. It plans to list on the Nasdaq under the symbol ADPT. Adaptive Biotechnologies filed confidentially on March 29, 2019. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. No pricing terms were disclosed.
